Clinical trial
A Double-blind, Placebo Controlled, Randomized Multicenter Phase II Study Evaluating Gemcitabine With or Without Ramucirumab as II Line Treatment for Advanced Malignant Pleural Mesothelioma
NCT03560973 is registered in ClinicalTrials.gov with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Placebo Controlled, Randomized Multicenter Phase II Study Evaluating Gemcitabine With or Without Ramucirumab as II Line Treatment for Advanced Malignant Pleural Mesothelioma
- Lead sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 22, 2016
- Completion date
- July 20, 2022
- Enrollment
- 164 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.